As of Friday close, Autolus Therapeutics plc’s (NASDAQ:AUTL) stock was up $0.21, moving up 7.14 percent to $3.15. The average number of shares traded per day over the past five days has been 412,920 shares. 3 times new highs have been achieved over the past 5 days, with a $0.39 gain in that time frame. In the last twenty days, the average volume was 462,075, while in the previous 50 days, it was 496,448.
Since last month, AUTL stock rose 15.38%. Shares of the company fell to $2.59 on 07/19/23, the lowest level in the past month. A 52-week high of $3.77 was reached on 05/23/23 after having rallying from a 52-week low of $1.60. Since the beginning of this year, AUTL’s stock price has risen by 65.79% or $1.25, and marked a new high 12 times. However, the stock has declined by -16.45% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
The stock’s beta is 1.48. Besides these, the trailing price-to-sales (P/S) ratio of 76.91, the price-to-book (PB) ratio of 2.05.
Financial Health
In the three months ended June 29, Autolus Therapeutics plc’s quick ratio stood at 9.90, while its current ratio was 9.90, showing that the company is able to pay off its debt. Based on annual data, AUTL earned $174.41 million in gross profit and brought in $6.36 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -48.10%. Return on equity (ROE) for the past 12 months was -63.30%.
AUTL’s revenue fell -382.35% during the quarter, while net income inched up to $0.17 million. While analysts expected Autolus Therapeutics plc to report -$0.22 quarterly earnings, the actual figure was -$0.26 per share, beating the consensus estimate by -18.20%. During the quarter, the company generated -$46.38 million in EBITDA. The liabilities of Autolus Therapeutics plc were 221.66 million at the end of its most recent quarter ended June 29, and its total debt was $50.94 million.
Technical Picture
This quick technical analysis looks at Autolus Therapeutics plc’s (AUTL) price momentum. With a historical volatility rate of 78.26%, the RSI 9-day stood at 63.89% on 18 August.
With respect to its five-day moving average, the current Autolus Therapeutics plc price is up by +14.13% percent or $0.39. At present, AUTL shares trade +9.76% above its 20-day simple moving average and +70.27% percent above its 100-day simple moving average. However, the stock is currently trading approximately +6.78% above its SMA50 and +10.53% above its SMA200.
Stochastic coefficient K was 40.88% and Stochastic coefficient D was 24.90%, while ATR was 0.20. Given the Stochastic reading of 75.91% for the 14-day period, the RSI (14) reading has been calculated as 60.68%. As of today, the MACD Oscillator reading stands at 0.03, while the 14-day reading stands at -0.02.
Analyst Ratings
Autolus Therapeutics plc (AUTL) has been rated Overweight by analysts. According to 0 brokerage firms, AUTL is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Autolus Therapeutics plc stock as buy, with 8 recommending it as overweight.
With a median target price of $6.50, the current consensus forecast for the stock is $2.80 – $12.00. Based on these forecasts, analysts predict Autolus Therapeutics plc (AUTL) will achieve an average price target of $7.38.
